Market Closed -
London S.E.
09:05:12 03/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
28
GBX
|
+0.18%
|
|
-0.88%
|
+17.89%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
11.58
|
172.4
|
154.3
|
67.09
|
190.5
|
190.5
|
-
|
Enterprise Value (EV)
1 |
13.81
|
152.8
|
138.9
|
38.65
|
161.6
|
146.7
|
136.3
|
P/E ratio
|
-1.27
x
|
-14.3
x
|
-2,300
x
|
-83.3
x
|
10.1
x
|
22.5
x
|
20
x
|
Yield
|
-
|
-
|
-
|
-
|
1.45%
|
0.84%
|
0.86%
|
Capitalization / Revenue
|
1.36
x
|
7.84
x
|
3.96
x
|
1.38
x
|
2.88
x
|
3.03
x
|
2.81
x
|
EV / Revenue
|
1.63
x
|
6.95
x
|
3.56
x
|
0.8
x
|
2.88
x
|
2.33
x
|
2.01
x
|
EV / EBITDA
|
-3.54
x
|
-22.9
x
|
48.1
x
|
4.26
x
|
12.4
x
|
10.3
x
|
8.79
x
|
EV / FCF
|
-4.65
x
|
45.6
x
|
-
|
2.64
x
|
14.2
x
|
13
x
|
9.06
x
|
FCF Yield
|
-21.5%
|
2.19%
|
-
|
37.8%
|
7.03%
|
7.7%
|
11%
|
Price to Book
|
2.47
x
|
6.45
x
|
-
|
3.32
x
|
6.06
x
|
3.98
x
|
3.4
x
|
Nbr of stocks (in thousands)
|
2,54,573
|
6,68,052
|
6,70,929
|
6,70,929
|
6,80,372
|
6,80,372
|
-
|
Reference price
2 |
0.0455
|
0.2580
|
0.2300
|
0.1000
|
0.2800
|
0.2800
|
0.2800
|
Announcement Date
|
24/06/20
|
17/06/21
|
07/06/22
|
25/04/23
|
09/04/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
8.494
|
22
|
39
|
48.48
|
56.04
|
62.91
|
67.88
|
EBITDA
1 |
-
|
-3.906
|
-6.669
|
2.888
|
9.072
|
13.04
|
14.19
|
15.51
|
EBIT
1 |
-
|
-4.554
|
-8.317
|
0.857
|
6.142
|
10.32
|
10.78
|
12.09
|
Operating Margin
|
-
|
-53.62%
|
-37.81%
|
2.2%
|
12.67%
|
18.42%
|
17.13%
|
17.82%
|
Earnings before Tax (EBT)
1 |
-
|
-5.998
|
-11.16
|
0.277
|
-0.365
|
11.15
|
11.28
|
12.8
|
Net income
1 |
-1.47
|
-5.929
|
-10.79
|
-0.074
|
-0.776
|
16.12
|
8.9
|
10
|
Net margin
|
-
|
-69.8%
|
-49.06%
|
-0.19%
|
-1.6%
|
28.75%
|
14.15%
|
14.73%
|
EPS
2 |
-6.969
|
-0.0359
|
-0.0180
|
-0.000100
|
-0.001200
|
0.0235
|
0.0124
|
0.0140
|
Free Cash Flow
1 |
-
|
-2.97
|
3.353
|
-
|
14.62
|
10.95
|
11.3
|
15.05
|
FCF margin
|
-
|
-34.97%
|
15.24%
|
-
|
30.16%
|
19.27%
|
17.95%
|
22.17%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
161.14%
|
89.99%
|
79.61%
|
97.02%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
126.95%
|
126.91%
|
150.49%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
0.004050
|
0.002350
|
0.002410
|
Announcement Date
|
19/06/19
|
24/06/20
|
17/06/21
|
07/06/22
|
25/04/23
|
09/04/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
2.23
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
19.6
|
15.4
|
28.4
|
34.8
|
43.8
|
54.2
|
Leverage (Debt/EBITDA)
|
-
|
-0.5709
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-2.97
|
3.35
|
-
|
14.6
|
10.9
|
11.3
|
15
|
ROE (net income / shareholders' equity)
|
-
|
-171%
|
-39.2%
|
-
|
30.8%
|
33.1%
|
19.9%
|
19.7%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
0.0200
|
0.0400
|
-
|
0.0300
|
0.0500
|
0.0700
|
0.0800
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-
|
0.0200
|
0.0200
|
0.0200
|
Capex
1 |
-
|
0.02
|
0.82
|
0.74
|
1.36
|
2.25
|
3.89
|
2.03
|
Capex / Sales
|
-
|
0.29%
|
3.72%
|
1.89%
|
2.81%
|
3.96%
|
6.18%
|
2.99%
|
Announcement Date
|
19/06/19
|
24/06/20
|
17/06/21
|
07/06/22
|
25/04/23
|
09/04/24
|
-
|
-
|
Last Close Price
0.28
GBP Average target price
0.3607
GBP Spread / Average Target +28.82% Consensus |
1st Jan change
|
Capi.
|
---|
| +17.89% | 238M | | +25.69% | 48.09B | | +46.90% | 40.62B | | -3.46% | 40.43B | | -6.20% | 28.36B | | +9.17% | 24.89B | | -20.42% | 19.01B | | +28.07% | 12.09B | | +0.17% | 11.88B | | -1.24% | 11.8B |
Other Biotechnology & Medical Research
|